MA-NETSCOUT-SYSTEMS
25.4.2024 12:06:33 CEST | Business Wire | Press release
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) today released findings from its 2H2023 DDoS Threat Intelligence Report that dissects trends and attack methodologies adversaries use against service providers, enterprises, and end-users. The information cited in the report is gathered from NETSCOUT’s unparalleled internet visibility at a global scale, collecting, analyzing, prioritizing, and disseminating data on DDoS attacks from 214 countries and territories, 456 vertical industries, and more than 13,000 Autonomous System Numbers (ASNs). Driven by tech-savvy and politically motivated hacktivist groups and an increase in DNS water torture attacks, NETSCOUT observed more than 7 million DDoS attacks in the second half of 2023, representing a 15% increase from the first half.
Hacktivism Increases Ten-Fold
DDoS (Distributed Denial-of-Service) hacktivism transcended geographic borders during the past year, exemplifying a shift in the global security landscape. Groups like NoName057(016) and Anonymous Sudan, as well as lone hackers and small collectives, are increasingly using DDoS to target those ideologically opposed to them, for example:
- Peru experienced a 30% increase in attacks tied to protests of former Peruvian President Fujimori’s release from prison on December 6.
- Poland experienced a surge in attacks at the end of 2023 associated with a regime change and statements reaffirming Poland’s support of Ukraine in the Russia-Ukraine conflict.
- Anonymous Sudan attacked X (formerly Twitter) to influence Elon Musk regarding Starlink service in Sudan, and it attacked Telegram for suspending its main channel.
NoName057(016), Anonymous Sudan, and Killnet have taken credit for DDoS attacks in Ukraine, Russia, Israel, and Palestine targeting communications infrastructure, hospitals, and banks. Daily attacks from hacktivists increased more than ten-fold between the first and second halves of 2023. NoName057(016) topped the list of DDoS adversaries in 2023, targeting 780 websites across 35 countries.
Water Torture Attacks Rise
Targeting critical systems at the heart of the Internet's control plane, DNS (Domain Name System) water torture attacks have been on the rise since the end of 2019. DNS query floods designed to overwhelm authoritative DNS servers experienced a massive 553% increase from 1H2020 to 2H2023. Rather than targeting one website or server, adversaries go after entire systems, resulting in even more damage.
Gaming and Gambling Targeted
NETSCOUT findings point to gaming -- and the gambling associated with gaming – as a primary target for DDoS attacks. Threat actors are drawn to the sector’s substantial financial value and the goal of disrupting competitors, especially during online esports tournaments. Historically, 80-90% of all DDoS attacks are related to gaming and gambling. NETSCOUT assessed attacks on enterprises in these sectors, determining that more than 100,000 DDoS attacks were deployed against those in gaming, and over 20,500 were made against those tied to gambling in 2023.
In addition, based on NETSCOUT’s observations of the DDoS threat landscape, approximately 1% of DDoS attacks are suppressed from originating networks.
“Global adversaries have become more sophisticated in the past year attacking websites and overloading servers to lockout customers and inflict digital chaos to influence geopolitical issues,” stated Richard Hummel, senior threat intelligence lead, NETSCOUT. “The relentless barrage of DDoS threats drives up costs and creates security fatigue for network operators. They cannot safeguard their digital assets without the proper advanced DDoS protection leveraging predictive, real-time threat intelligence.”
Multiple decades of experience working with the world’s largest service providers and enterprises give NETSCOUT far-reaching visibility into the global internet to discern the pulse of the digital world. Our capacity to monitor and respond to DDoS attacks is powered by our ATLAS platform, which enables us to analyze an impressive 500 terabits per second (Tbps) of network traffic.
Visit our interactive website for more information on NETSCOUT's DDoS Threat Intelligence Report. For real-time DDoS attack stats, map, and insights, visit NETSCOUT Cyber Threat Horizon.
About NETSCOUT
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) protects the connected world from cyberattacks and performance and availability disruptions through the company’s unique visibility platform and solutions powered by its pioneering deep packet inspection at scale technology. NETSCOUT serves the world’s largest enterprises, service providers, and public sector organizations. Learn more at www.netscout.com or follow @NETSCOUT on LinkedIn, X, or Facebook.
©2024 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Visibility Without Borders, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, Omnis, and TrueCall are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240425443965/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
